Evidence map›Paper›PMID 36996065›Full record

Trial reportPloS one2023

Prevention of relapse in drug sensitive pulmonary tuberculosis patients with and without vitamin D3 supplementation: A double blinded randomized control clinical trial.

Sanjeev Sinha, Himanshu Thukral, Imtiyaz Shareef, Devashish Desai, Binit Kumar Singh, Bimal Kumar Das, Sahajal Dhooria, Rohit Sarin, Rupak Singla, Saroj Kumari Meena and 8 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Host-directed therapy for tuberculosis.European journal of medical research · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Sanjeev SinhaDepartment of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.ORCID 0000-0001-8060-4231
Himanshu ThukralDepartment of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Imtiyaz ShareefDepartment of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Devashish DesaiDepartment of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Binit Kumar SinghDepartment of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Bimal Kumar DasDeparment of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Sahajal DhooriaDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Rohit SarinDepartment of Respiratory Medicine, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
Rupak SinglaDepartment of Respiratory Medicine, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
Saroj Kumari MeenaDepartment of Respiratory Medicine, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
Ravindra Mohan PandeyDepartment of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Shivam PandeyDepartment of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Sunil SethiDepartment of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Ashumeet KajalDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Rakesh YadavDepartment of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Ashutosh Nath AggarwalDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Sanjay BhadadaDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Digambar BeheraDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
All India Institute of Medical Sciences · INPost Graduate Institute of Medical Education and Research · INLRS Institute of Tuberculosis and Respiratory Diseases · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe immunomodulatory effects of vitamin D are widely recognized and a few studies have been conducted to determine its utility in the treatment of tuberculosis, with mixed results. This study was conducted to see if vitamin D supplementation in patients with active pulmonary tuberculosis (PTB) in the Indian population contributed to sputum smear and culture conversion as well as the prevention of relapse.

methodsThis randomized double-blind placebo-controlled trial was conducted in three sites in India. HIV negative participants aged 15-60 years with sputum smear positive PTB were recruited according to the Revised National Tuberculosis Control Program guidelines and were randomly assigned (1:1) to receive standard anti-tubercular treatment (ATT) with either supplemental dose of oral vitamin D3 (60,000 IU/sachet weekly for first two months, fortnightly for next four months followed by monthly for the next 18 months) or placebo with same schedule. The primary outcome was relapse of PTB and secondary outcomes were time to conversion of sputum smear and sputum culture.

resultsA total of 846 participants were enrolled between February 1, 2017 to February 27, 2021, and randomly assigned to receive either 60,000 IU vitamin D3 (n = 424) or placebo (n = 422) along with standard ATT. Among the 697 who were cured of PTB, relapse occurred in 14 participants from the vitamin D group and 19 participants from the placebo group (hazard risk ratio 0.68, 95%CI 0.34 to 1.37, log rank p value 0.29). Similarly, no statistically significant difference was seen in time to sputum smear and sputum culture conversion between both groups. Five patients died each in vitamin D and placebo groups, but none of the deaths were attributable to the study intervention. Serum levels of vitamin D were significantly raised in the vitamin D group as compared to the placebo group, with other blood parameters not showing any significant difference between groups.

conclusionsThe study reveals that vitamin D supplementation does not seem to have any beneficial effect in the treatment of PTB in terms to the prevention of relapse and time to sputum smear and culture conversion.

trial registrationCTRI/2021/02/030977 (ICMR, Clinical trial registry-India).

Indexed as

CholecalciferolTuberculosis, PulmonaryDietary SupplementsDouble-Blind MethodHumansRecurrenceTreatment OutcomeVitamin DVitaminsCholecalciferolVitamin DVitamins

Identifiers

PMID36996065
PMCPMC10062618
OpenAlexW4361267214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.